Jump to any asset
849 assets, updated daily
As of September 27, 2026, AbbVie Inc. (ABBV) trades at $264.34. CleaRank Financial AI rates it Buy with a fair value of $283.50, 7.2% above the current price. Wall Street's consensus target is $283.50 across 30 analysts. RSI at 65 is in neutral territory, and the price is above its 50-day average of $257.05.
AbbVie Inc. (ABBV)
AbbVie Inc. NYSE
$264.34
-0.7800 (-0.29%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
75 / 100
AbbVie Inc. (ABBV) is trading at $264.34, above its 50-day and 200-day moving averages ($257.05 and $230.56), indicating positive technical momentum. The company is positioned for significant growth, with Wall Street analysts projecting a 40.1% EPS increase in the current year and 16.1% in the next, alongside revenue growth of 11.00% and 9.00% respectively. The median analyst price target of $283.5 suggests a 7.2% upside from the current price. While the company demonstrates strong profitability with a 40.04% operating margin and a 9.80% net profit margin, its return on equity is negative at -129.68%. The valuation appears stretched with a P/E ratio of 74.46, significantly higher than the sector median of 31.9, and a price-to-sales ratio of 7.25 compared to the sector average of 3.7. However, the forward growth estimates provide some justification for this premium.
ABBV Price Analysis
Market Metrics
Open
$265.49
Day Range
$262.59 to $266.00
Prev Close
$265.12
Volume
2.54M
52-Week Range
$190.75 to $269.39
Market Cap
$467.12B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a significant premium to sector peers (+133%), suggesting market expectations for superior growth or market position.
ABBV Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, ABBV beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats.
ABBV Analysis
Company's Health
4/5
12-Month Analyst Target
+7.25% Upside
Median of 30 analysts (12-month)
$283.50
AI Technical Analysis
At $264.34, AbbVie Inc. is trading above its 50-day SMA of $257.05 and its 200-day SMA of $230.56, signaling a bullish trend. The Relative Strength Index (RSI) is at 65.02, indicating bullish momentum without being overbought. Key support levels are near the 50-day SMA, while resistance is implied by the median analyst target price of $283.5. Volume has been below average recently, suggesting a lack of strong conviction behind the current price action. The chart structure indicates continued upward potential, provided key support levels hold.
ProTips
- Monitor insider selling trends closely, as a significant increase could signal waning management confidence.
- Given the stock is trading above its 50-day and 200-day moving averages ($257.05 and $230.56), consider using these levels as potential support zones for entry or stop-loss points.
- The company's high P/E ratio relative to its sector suggests that future growth must meet or exceed expectations to justify the current valuation.
Key Catalysts
Bullish
Strong Forward Growth Estimates
Analysts project significant EPS and revenue growth for the current and next year, providing a fundamental basis for continued stock appreciation.
Source: Wall Street EstimatesBullish
Positive Technical Momentum
The stock is trading above key moving averages (50-day and 200-day SMA) with a bullish RSI, indicating favorable short-to-medium term price action.
Source: Technical AnalysisBearish
Elevated Valuation Metrics
AbbVie's P/E and Price-to-Sales ratios are substantially higher than sector averages, creating risk if growth falters.
Source: Fundamental AnalysisBearish
Moderate Insider Selling
Significant insider selling totaling $42.3 million across 44 transactions suggests a lack of immediate buying conviction from management.
Source: Insider TransactionsMarket Outlook
AbbVie Inc. is expected to continue its growth trajectory, driven by strong forward earnings and revenue estimates. The median analyst target price of $283.5 suggests a modest upside from the current trading level, supported by positive technical indicators and a solid operational margin. However, the company's premium valuation and negative return on equity present potential headwinds. Any significant slowdown in growth or a shift in market sentiment towards value stocks could pressure the stock. Investors should monitor upcoming earnings reports and pipeline developments closely.
Key Statistics
| Market Cap | 467.12B |
|---|---|
| P/E Ratio | 74.46 |
| EPS (TTM) | 3.55 |
| Dividend Yield | 2.58% |
| 52 Week High | 269.39 |
| 52 Week Low | 190.75 |
AbbVie Inc. (ABBV) trades at a P/E ratio of 74.46, significantly above the Healthcare sector median of 31.9, and its price-to-sales ratio of 7.25 is also elevated compared to the sector average of 3.7. Despite this premium valuation, the company boasts strong operational efficiency with a 40.04% operating margin and a 9.80% net profit margin. The company's balance sheet shows a negative debt-to-equity ratio of -0.12, indicating minimal leverage. However, the return on equity is a concerning -129.68%. The forward growth estimates, with projected EPS growth of 40.1% for the current year and 16.1% for the next, are critical in justifying the current valuation multiples.
Earnings & Growth Analysis
AbbVie Inc. most recently reported earnings for the quarter ending June 2026, with an actual EPS of $3.65, beating the estimate of $3.61 by 1.11%. This followed a slight miss in the prior quarter. The company has shown a mixed pattern of beating and missing estimates in recent quarters, but the overall trend in EPS estimates for the current and next year remains strong, with projected growth of 40.1% and 16.1% respectively.
Key Risks
A primary risk for AbbVie Inc. is its elevated valuation, with a P/E ratio significantly higher than its sector peers, which could lead to a sharp correction if growth expectations are not met. Moderate insider selling, with $42.3 million in sales across 44 transactions, warrants attention as it may signal a lack of immediate conviction from management. Also, the negative return on equity of -129.68% raises concerns about the company's ability to generate profits from its equity base. While forward growth estimates are strong, any deceleration could put pressure on the current stock price.
Technical Indicators
| RSI (14) | 65.02 |
|---|---|
| MACD | 2.61 |
| SMA 50 | 257.05 |
| SMA 200 | 230.56 |
RSI
Bullish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($257.05) above the 200-day SMA ($230.56), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.16
Weak correlation
Nasdaq 100 (QQQ)
+0.04
Weak correlation
Bitcoin (BTC)
-0.02
Weak correlation
Gold (XAU)
+0.02
Weak correlation
Check Custom Correlation
How does any other asset move with ABBV? One year of daily closes, Pearson correlation.
Try
ABBV Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$259.05
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$264.34
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$251.28
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (65.0) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$272.01
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$284.96
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$297.91
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for ABBV is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in ABBV in September 2016 would be worth about $40,939 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ABBV today could grow to about $28,290 by 2036 in the base case, with a bull case near $82,143 and a bear case around $9,743. Projections are statistical simulations, not guarantees.
ABBV Stock Price Prediction: 2030
CleaRank's simulation projects a price near $401 for ABBV by 2030 in the base case, from $264 today (1.5x over 4 years). The downside path ends near $204. These are outcomes of a Monte Carlo simulation run on ABBV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $209 | $293 | $411 |
| 2028 | $202 | $325 | $524 |
| 2029 | $201 | $361 | $647 |
| 2030 | $204 | $401 | $786 |
| 2031 | $209 | $445 | $945 |
| 2032 | $216 | $493 | $1,127 |
| 2033 | $224 | $547 | $1,335 |
| 2034 | $234 | $607 | $1,576 |
| 2035 | $245 | $674 | $1,853 |
| 2036 | $258 | $748 | $2,171 |
Method: 10,000 simulated price paths using ABBV's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
ABBV Insider Trading Analysis
Bought
None
No open-market buys
Sold
$42.3M
7 Transactions
Insiders
23
Active Traders
Avg Transaction
$6.0M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 28, 2020 | Norges Bank Investment Management
|
Sell | 1.1M | $88.2M |
| Jul 17, 2024 | GONZALEZ RICHARD A
Officer and Director
|
Sell | 282.8K | $49.5M |
| May 10, 2022 | SEVERINO MICHAEL E
Officer
|
Sell | 300.0K | $45.3M |
| May 17, 2022 | SEVERINO MICHAEL E
Officer
|
Sell | 200.0K | $30.8M |
| Feb 28, 2024 | GONZALEZ RICHARD A
Chief Executive Officer
|
Sell | 138.6K | $24.6M |
| Dec 17, 2021 | SCHUMACHER LAURA J
Officer
|
Sell | 181.7K | $23.7M |
| Nov 12, 2020 | GONZALEZ RICHARD A
Chief Executive Officer
|
Sell | 231.6K | $22.4M |
| Dec 9, 2021 | GONZALEZ RICHARD A
Chief Executive Officer
|
Sell | 174.1K | $21.5M |
| Apr 21, 2020 | Norges Bank Investment Management
|
Sell | 259.0K | $20.8M |
| Mar 3, 2025 | GONZALEZ RICHARD A
Director
|
Sell | 98.6K | $20.3M |
Page 1 of 1
Frequently Asked Questions
What is AbbVie Inc.'s stock price forecast for 2030?
Based on a Monte Carlo simulation, AbbVie Inc.'s stock price is projected to be $400.7 in 2030 under a base case scenario. The downside projection is $204.18, and the upside projection is $786.33. These are statistical outcomes, not guarantees.
Is AbbVie Inc. stock a buy right now?
AbbVie Inc. is currently rated a Buy with a consensus score of 75. The stock is trading above key moving averages, and Wall Street analysts have a median price target of $283.5, suggesting a modest upside.
What are the key technical indicators for AbbVie Inc.?
AbbVie Inc. is trading above its 50-day and 200-day moving averages ($257.05 and $230.56), indicating a bullish trend. The RSI is at 65.02, showing bullish momentum, and the MACD is positive at 2.61.
How does AbbVie Inc.'s valuation compare to its sector peers?
AbbVie Inc.'s P/E ratio of 74.46 and price-to-sales ratio of 7.25 are significantly higher than the Healthcare sector medians of 31.9 and 3.7, respectively, suggesting it trades at a premium.
What is the recent insider trading activity for AbbVie Inc.?
Insiders at AbbVie Inc. are net sellers, with $42.3 million in total sales in recent filings and no reported purchases. This indicates a moderate sell signal from management.
What are the forward earnings and revenue growth estimates for AbbVie Inc.?
Analysts project AbbVie Inc.'s EPS to grow by 40.1% in the current year and 16.1% next year. Revenue is expected to increase by 11.00% this year and 9.00% next year.
What are the main risks facing AbbVie Inc.?
Key risks include its high valuation relative to peers, a negative return on equity, and moderate insider selling. Any failure to meet aggressive growth expectations could negatively impact the stock price.